JAK Janus Kinase
(Unterschied zwischen Versionen)
| Zeile 12: | Zeile 12: | ||
{{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19 |pdf=|usr=}} | {{tp|p=32259575|t=ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19 |pdf=|usr=}} | ||
{{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}} | {{tp|p=32333918|t=ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact |pdf=|usr=}} | ||
| + | |||
| + | '''Fedratinib''' | ||
| + | {{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 10:55 Uhr
32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19
Tofacitinib
32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib
Baricitinib
32259575 ä. BARICITINIB - A JANUASE KINASE INHIBITOR - NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19
32333918 ä. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
Fedratinib
| 32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |
